Team

Stephen Bloch, MD

As an entrepreneur, venture capitalist and former practicing physician, Steve knows firsthand the challenges of building successful healthcare companies. Unfazed by complexity in healthcare, whether scientific, regulatory, or market driven, Steve’s mission has been to make healthcare delivery more effective and affordable.

Before co-founding EvolveImmune, Steve helped start and finance leading healthcare companies as a general partner at Canaan Partners. Steve has served on the boards of companies in biopharma, digital health, medical devices and diagnostics, often as board chairman. Steve is currently chairman of the board at Liquidia (NASDAQ: LQDA), executive chairman of Allyx Therapeutics and is a member of Dartmouth Medical School’s Board of Advisors. Steve was BioCT’s Entrepreneur of the Year in 2023.

Before joining Canaan in 2002, Steve helped found and manage multiple start-ups, including RMS, one of the first radiology benefits companies where he was CEO for 6 years. Previously, Steve was a strategic pharmaceutical consultant for Arthur D. Little and a Ewing Marion Kauffman Fellow.

Steve obtained his AB from Dartmouth College, a MA in the history of science from Harvard, and his medical degree from the University of Rochester. Steve completed his residency at Massachusetts General Hospital/Harvard Medical School (radiology) and Lenox Hill Hospital/Cornell Medical School (internal medicine).

Jay Fine, PhD

Jay brings over 30 years of drug discovery and development experience, including strong strategic leadership in discovery research, translational sciences and biomarker research covering immunology, immuno-oncology, inflammatory diseases and tissue fibrosis.

Prior to joining EvolveImmune, Jay was the Senior Vice President and Global Therapeutic Area Head for Immunology & Respiratory Diseases Research at Boehringer Ingelheim and the US Discovery Research Site Head at their Ridgefield, CT headquarters. Jay’s teams played seminal roles in the advancement of Skyrizi™ and Spevigo™, and delivered over 25 molecules into clinical development.

Previously, Jay held positions of increasing responsibility at Roche, Schering-Plough and the National Cancer Institute. He received his BS degree from Cornell University and his Ph.D. degree from the University of Rochester Medical Center. He is the author of over 75 scientific publications and patents, and has received numerous honors and awards throughout his career.

Jeremy Myers, PhD

Jeremy Myers leads EvolveImmune’s biology and biotherapeutic research teams.

Before joining EV Jeremy helped lead Pfizer oncology research and development in Pearl River, NY as senior director, head of the Integrative Biotechnology Group. He was a member of Pfizer Oncology Research and Development Leadership Team. During his tenure, Jeremy led development of tumor targeted immunotherapies leveraging antibody discovery and rational protein design, cell surface antigen discovery efforts and interrogation of biotherapeutic targets for antibody drug conjugates and T-cell retargeting bispecific antibody therapeutics.

Before Pfizer, Jeremy was a research faculty member and AstraZeneca Research Fellow in the Department of Biochemistry at Vanderbilt University Medical School. Jeremy received his BSc in biology from Bucknell University. He completed his Ph.D. studies in biochemistry and molecular biology at the LSU Health Sciences Center and Louisiana State University. He completed a postdoctoral fellowship at Vanderbilt University.

Jennifer Gabler, MBA

Jen has over twenty five years of experience as a CFO for venture backed and startup companies.

As the CFO for Extraprise (now Vericast), a marketing services company, Jen built finance, HR, IT and back office operations plus helped lead global M&A efforts. She has also been the CFO for Aldea Pharmaceuticals and Butterfly Health, and provided financial project support for Marinus Pharmaceuticals (MRNS-NASDAQ) and Allyx Therapeutics. Jen began her career as an investment banking analyst at Merrill Lynch, and was the Northeast controller and a senior manager in entrepreneurial services at Coopers & Lybrand.

Jen co-founded The Refinery (www.refineryct.com), an accelerator for early stage companies with diverse management teams. She is also a founding partner of Marlborough Street Partners (www.marlboroughst.com) which provides strategic and operational services for investors and venture-funded companies.

Jen has an AB from Dartmouth College, an MBA from Columbia Business School and is a licensed CPA. She has been a lecturer and researcher at both Tuck and Harvard Business Schools.

Michael Franken, MD

Michael brings over 25 years of biotech industry experience and strong business leadership in immunology, rare diseases, and transplant and hematology.

Prior to joining EvolveImmune, Michael was the Chief Business Officer at LogicBio Therapeutics Inc., a public biotech company focused on developing novel genomics medicines for patients with early onset genetic diseases. Until its acquisition by AstraZeneca, Michael was a member of the executive leadership team with responsibility for the company’s business development, strategy and commercial functions with a focus on executing strategic business deals, including the execution of several collaboration and license agreements with large pharmaceutical companies.

Previously, Michael co-founded and managed multiple biotech start-ups, and was in senior leadership roles at Momenta Pharmaceuticals (now Johnson & Johnson), Radius Health and Genzyme Corporation (now Sanofi). During his more than 10-year tenure at Genzyme, Michael held progressively senior positions in corporate development and deal making, drug development and as VP and General Manager, Transplant, was successful in driving significant growth of Genzyme’s commercial transplant business.

Michael received his MD degree from the University of Heidelberg, Germany and his Master’s degree in Health Policy and Management from the Harvard School of Public Health.

Mark Aimone, MBA

Mark Aimone brings over 30 years of CMC, supply chain and strategic sourcing experience, including operational leadership within R&D and manufacturing organizations.  He has responsibility for building and leading EvolveImmune’s CMC development function and manufacturing operations.

Prior to joining EvolveImmune, Mark was Vice President at Alexion-AstraZeneca Rare Disease Business Unit where he built and led the CMC Leadership group. In addition, Mark had overall responsibility for the rare disease clinical supply chain including internal and external (CDMO) development, manufacturing, packaging, and distribution operations.

He joined Alexion in 2016 and played a pivotal role in bringing Ultomiris (ravulizumab, humanized monoclonal antibody complement inhibitor) into Phase 3 and approval in 2018. He chaired cross functional CMC governance and was a senior member of the Product Development and Clinical Supply Leadership team within Research and Development.

Prior to joining Alexion in 2016, Mark held positions of increasing responsibility at Pfizer in Groton, CT. Mark had responsibility for the CMC leadership groups for both Primary and Specialty Care at Pfizer and held clinical supply, strategic sourcing and technology transfer positions over his 20-year career. Mark received his Bachelor’s degree from Villanova University and his MBA from Rensselaer Polytechnic Institute.

Tony Fiorino, MD, PhD

Tony is a physician-scientist with over 25 years’ experience in the biopharmaceutical industry, including over 15 years as a drug developer and as a public and private biotechnology CEO and CMO, which followed a 10-year career as a healthcare analyst and hedge fund manager. Tony has run programs ranging from late-stage preclinical through phase 4 in oncology, inflammatory/immune disease, and neurology, across small molecules, biologics, cell therapies and medical devices, and brings extensive experience in both clinical development/regulatory strategy as well as study-level operational considerations, and provides hands-on and engaged program leadership. For the past two years, Tony has been an independent clinical development consultant, work with large and small biopharmaceutical companies on a variety of strategic and clinical development engagements, and before that he was Vice President, Clinical Development at Zentalis Pharmaceuticals.

Over the past 10 years, Tony has been deeply involved with multiple early-stage oncology programs and first-in-human oncology studies, which have included a BCL-2 inhibitor, a 3rd generation EGFR inhibitor, an Ikaros degrader, a non-CAR-T engineered T cell platform, and a dual-targeted monoclonal antibody, being developed in both hematologic malignancies and solid tumors. His prior roles include CEO of EnzymeRx (sold to 3SBio), Triumvira Immunologics, and BrainStorm Cell Therapeutics, and CMO of Immune Pharmaceuticals and electroCore. Before founding EnzymeRx, Tony was an analyst and portfolio manager at several firms including JP Morgan, Citigroup, and Pequot Asset Management. Tony received a BS in Biology from MIT, an MD and PhD from the Albert Einstein College of Medicine, and trained in medicine and dermatology at the Hospital of the University of Pennsylvania.